CTOR (Citius Oncology) Non Operating Income: $1.76 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CTOR Citius Oncology Inc CTOR
10 GF Score
Price $0.53
! 2 Warning Signs
View Full Analysis

What is Citius Oncology Non Operating Income?

Citius Oncology CTOR -0.94% 10 Non Operating Income is $1.76 Mil as of Mar. 2026. GuruFocus rates CTOR with a GF Score™ of 10/100. The stock has 2 warning signs investors should review.

Non Operating Income is income or expense that comes from miscellaneous sources. Citius Oncology's Non Operating Income for the three months ended in Mar. 2026 was $1.76 Mil. Its Non Operating Income for the trailing twelve months (TTM) ended in Mar. 2026 was $1.76 Mil.

Citius Oncology Non Operating Income Related Terms

Citius Oncology Non Operating Income Historical Data

* Premium members only.

The historical data trend for Citius Oncology's Non Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Citius Oncology Non Operating Income Chart

Citius Oncology Annual Data
Trend Sep22 Sep23 Sep24 Sep25
Non Operating Income
0.00 0.00 0.00 0.00

Citius Oncology Quarterly Data
Sep22 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Non Operating Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 1.76
CTOR
10GF Score
Citius Oncology Inc CTOR
Non Operating Income is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Citius Oncology Non Operating Income Calculation

Non Operating Income is income or expense that comes from miscellaneous sources.

Non Operating Income for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.76 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Non Operating Income →
What does a Non Operating Income of $1.76 Mil mean?
Citius Oncology (CTOR) has a Non Operating Income of $1.76 Mil as of Mar. 2026. Non-operating Income represents the amount of income from one-time, nonrecurring events. View historical data on Citius Oncology and its competitors.
Is Citius Oncology's Non Operating Income too high?
Citius Oncology's current Non Operating Income is $1.76 Mil. Overall, Citius Oncology has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Citius Oncology's Non Operating Income compare to INCR and CPHI?
Citius Oncology's Non Operating Income of $1.76 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Non Operating Income for a Drug Manufacturers company?
A good Non Operating Income depends on the Drug Manufacturers industry context. However, Non Operating Income should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Non Operating Income mean?
A high Non Operating Income can signal that a stock is expensive relative to its fundamentals. Non-operating Income represents the amount of income from one-time, nonrecurring events. View historical data on Citius Oncology and its competitors. Citius Oncology's current Non Operating Income is $1.76 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Citius Oncology stock overvalued right now?
Citius Oncology (CTOR) has a current Non Operating Income of $1.76 Mil. The current Non Operating Income is $1.76 Mil. Citius Oncology's overall GF Score™ is 10/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Non Operating Income calculated?
Non Operating Income is calculated from a company's financial statements. For Citius Oncology (CTOR), the current Non Operating Income is $1.76 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Citius Oncology Business Description

Address 11 Commerce Drive, First Floor, Cranford, NY, USA, 07016
Citius Oncology Inc is a biopharmaceutical company focused on developing and commercializing targeted oncology therapies.The Company centers on achieving a market position by advancing therapies with reduced development and clinical risks, and competitive advantages supported by intellectual property and regulatory exclusivity protection. This includes new formulations of previously approved drugs with substantial existing safety and efficacy data or expanded indications for approved therapies. The company focused on key geographies and stakeholders, majorly on cancer centers and patients.
10GF Score

Get the complete analysis for CTOR

Non Operating Income is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.53
Price